TrialAn Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Trial details
- Registry ID
- NCT04740476
- Phase
- Phase 2
STOK
Stoke Therapeutics, Inc
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeNCT04740476 | STOK | Phase 2 | Active not recruiting | 2029-03-31Estimated |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeNCT06872125 | STOK | Phase 3 | Recruiting | 2027-03Estimated |
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Trial details
- Registry ID
- NCT06872125
- Phase
- Phase 3
Latest recorded trial changes
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125 · Stoke Therapeutics, Inc
Planned enrollment increased by 20 participants
− Before
150 participants (planned)
+ After
170 participants (planned)
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
NCT04740476 · Stoke Therapeutics, Inc
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Safety of multiple doses of STK-001
+ After
Measure: Safety of multiple doses of zorevunersen
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
NCT04740476 · Stoke Therapeutics, Inc
Primary completion date changed
− Before
3 Feb 2026
+ After
31 Mar 2029
Recruitment status changed
− Before
Enrolling by invitation
+ After
Active not recruiting